Voyager Therapeutics (NASDAQ:VYGR) Shares Gap Down to $13.85

Voyager Therapeutics, Inc. (NASDAQ:VYGR – Get Rating)’s share price gapped down prior to trading on Tuesday . The stock had previously closed at $13.85, but opened at $13.48. Voyager Therapeutics shares last traded at $12.38, with a volume of 283,651 shares.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on VYGR. Truist Financial started coverage on Voyager Therapeutics in a research report on Wednesday, May 10th. They set a “buy” rating and a $18.00 target price on the stock. StockNews.com raised shares of Voyager Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, May 11th. TheStreet raised shares of Voyager Therapeutics from a “d” rating to a “c+” rating in a research note on Friday, May 19th. Finally, Oppenheimer assumed coverage on shares of Voyager Therapeutics in a report on Thursday, March 9th. They set an “outperform” rating and a $14.00 price target on the stock.

Voyager Therapeutics Stock Performance

The stock has a fifty day moving average of $8.66 and a 200-day moving average of $7.60. The company has a market cap of $569.94 million, a PE ratio of 5.74 and a beta of 1.12.

Voyager Therapeutics (NASDAQ:VYGR – Get Rating) last issued its earnings results on Tuesday, March 7th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.04). The company had revenue of ($1.55) million for the quarter, compared to analysts’ expectations of $12.71 million. Voyager Therapeutics had a negative net margin of 24.21% and a positive return on equity of 95.18%. As a group, equities analysts anticipate that Voyager Therapeutics, Inc. will post 1.01 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, VP Robert W. Hesslein sold 4,410 shares of Voyager Therapeutics stock in a transaction that occurred on Monday, March 20th. The shares were sold at an average price of $7.76, for a total transaction of $34,221.60. Following the completion of the sale, the vice president now owns 102,200 shares of the company’s stock, valued at $793,072. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Voyager Therapeutics news, CEO Alfred Sandrock sold 7,437 shares of the firm’s stock in a transaction dated Monday, April 3rd. The shares were sold at an average price of $7.83, for a total transaction of $58,231.71. Following the transaction, the chief executive officer now owns 214,618 shares of the company’s stock, valued at approximately $1,680,458.94. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Robert W. Hesslein sold 4,410 shares of the business’s stock in a transaction dated Monday, March 20th. The shares were sold at an average price of $7.76, for a total transaction of $34,221.60. Following the completion of the sale, the vice president now owns 102,200 shares of the company’s stock, valued at approximately $793,072. The disclosure for this sale can be found here. Insiders have sold 18,953 shares of company stock worth $147,684 in the last three months. Corporate insiders own 22.00% of the company’s stock.

Hedge Funds Weigh In On Voyager Therapeutics

Several institutional investors have recently bought and sold shares of the business. UBS Group AG bought a new stake in Voyager Therapeutics during the 1st quarter valued at $39,000. PDT Partners LLC purchased a new stake in shares of Voyager Therapeutics during the 2nd quarter worth $60,000. Royal Bank of Canada raised its holdings in Voyager Therapeutics by 1,746.8% in the third quarter. Royal Bank of Canada now owns 12,004 shares of the company’s stock worth $71,000 after purchasing an additional 11,354 shares in the last quarter. Gamco Investors INC. ET AL bought a new position in Voyager Therapeutics in the fourth quarter worth about $73,000. Finally, Delphia USA Inc. purchased a new stake in shares of Voyager Therapeutics during the fourth quarter valued at about $80,000. 59.58% of the stock is owned by hedge funds and other institutional investors.

Voyager Therapeutics Company Profile

(Get Rating)

Voyager Therapeutics, Inc is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guang Ping Gao, Mark A.